Is NKTR stock still a good buy after its 40% move higher, after Nektar Therapeutics (NASDAQ:NKTR) strong NKTR-181 data?
What Pfizer Inc (NYSE:PFE), Intel Corporation (NASDAQ:INTC), & Gilead Sciences (NASDAQ:GILD) Have In Common
Pfizer (NYSE:PFE) & Intel Corporation (NASDAQ:INTC) paid big bucks for growth, but Mobileye NV (NYSE:MBLY) is a bet on innovation.
A bidding war for Acadia Pharmaceuticals and Nuplazid is likely to ensue after buyout rumors last Friday. Great news for ACAD stock owners.
Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma
Acquisition predictions for 2017 that include VRX, GILD, AmEx, SPLK, & WFM being bought, and Takeda, Pfizer, Apple, IBM, and Kroger spending big.
In part 1 of a 2-part series David examines his top dividend stocks for 2017, which include GILD, AT&T, SBGL, PFE, and BP.
Four dividend stocks and two growth stocks to buy that will yield a $30,000 annual return or more on $250,000 over the next decade.